GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of MGNX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

MacroGenics stock price down 0.186% on Thursday
(Updated on Apr 18, 2024)

Sell candidate since Apr 16, 2024 Loss -3.66% PDF

The MacroGenics stock price fell by -0.186% on the last day (Thursday, 18th Apr 2024) from $16.10 to $16.07. It has now fallen 5 days in a row. During the last trading day the stock fluctuated 3.54% from a day low at $15.82 to a day high of $16.38. The price has fallen in 6 of the last 10 days and is down by -9.62% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -355 thousand shares and in total, 568 thousand shares were bought and sold for approximately $9.12 million.

The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 9.94% during the next 3 months and, with a 90% probability hold a price between $15.06 and $24.68 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

MGNX Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The MacroGenics stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $17.16 and $16.83. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, March 06, 2024, and so far it has fallen -25.15%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for MacroGenics stock

MacroGenics finds support from accumulated volume at $16.06 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.560 between high and low, or 3.54%. For the last week, the stock has had daily average volatility of 5.70%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (MGNX) For The Upcoming Trading Day Of Friday 19th

For the upcoming trading day on Friday, 19th we expect MacroGenics to open at $16.09, and during the day (based on 14 day Average True Range), to move between $14.88 and $17.26, which gives a possible trading interval of +/-$1.19 (+/-7.43%) up or down from last closing price. If MacroGenics takes out the full calculated possible swing range there will be an estimated 14.86% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $16.06 (0.06%) than the resistance at $17.26 (7.41%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is MacroGenics stock A Buy?

The MacroGenics stock holds several negative signals and despite the positive trend, we believe MacroGenics will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -3.604 Sell Candidate Unchanged

Predicted Opening Price for MacroGenics of Friday, April 19, 2024

Fair opening price April 19, 2024 Current price
$16.09 ( 0.124%) $16.07

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for MGNX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 16.65 3.61 %
R2 16.44 2.28 %
R1 16.30 1.46 %
Current price: 16.07
Support S1 15.88 -1.21 %
S2 15.74 -2.03 %
S3 15.53 -3.36 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 17.78 10.64 %
R2 17.43 8.46 %
R1 17.26 7.41 %
Current price 16.07
Support S1 16.06 -0.0622%
S2 15.93 -0.87%
S3 15.45 -3.89%

FAQ

What is the symbol for MacroGenics Stock and on which exchange is it traded?
The symbol for MacroGenics is MGNX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell MacroGenics Stock?
The MacroGenics stock holds several negative signals and despite the positive trend, we believe MacroGenics will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy MacroGenics Stock?
MacroGenics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy MacroGenics Stock.

What's the current price of MacroGenics Stock?
As of the end of day on the 2024-04-18, the price of an MacroGenics (MGNX) share was $16.07.

What is the 52-week high and low for MacroGenics Stock?
The 52-week high for MacroGenics Stock is $21.88 and the 52-week low is $4.29.

What is the market capitalization of MacroGenics Stock?
As of the 2024-04-18, the market capitalization of MacroGenics is 998.673M.

When is the next earnings date for MacroGenics?
The upcoming earnings date for MacroGenics is May 14, 2024.
Click to get the best stock tips daily for free!

About MacroGenics

MacroGenics MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The... MGNX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT